Logo image of 1VKTX.MI

VIKING THERAPEUTICS INC (1VKTX.MI) Stock Overview

Europe - BIT:1VKTX - US92686J1060 - Common Stock

21.43 EUR
-1.61 (-6.99%)
Last: 9/9/2025, 7:00:00 PM

1VKTX.MI Key Statistics, Chart & Performance

Key Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap2.41B
Shares112.44M
Float109.65M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.31
PEN/A
Fwd PEN/A
Earnings (Next)10-21 2025-10-21/amc
IPO04-29 2015-04-29
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


1VKTX.MI short term performance overview.The bars show the price performance of 1VKTX.MI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

1VKTX.MI long term performance overview.The bars show the price performance of 1VKTX.MI in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 1VKTX.MI is 21.43 EUR.

VIKING THERAPEUTICS INC / 1VKTX Daily stock chart

1VKTX.MI Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 20.64 330.35B
AMG.DE AMGEN INC 12.77 128.24B
GIS.DE GILEAD SCIENCES INC 15.06 123.73B
VX1.DE VERTEX PHARMACEUTICALS INC 23.27 86.52B
ARGX.BR ARGENX SE 87.2 39.44B
22UA.DE BIONTECH SE-ADR N/A 20.45B
IDP.DE BIOGEN INC 9.23 18.55B
1MRNA.MI MODERNA INC N/A 8.36B
0QF.DE MODERNA INC N/A 8.31B
1EXAS.MI EXACT SCIENCES CORP N/A 7.29B
ABVX.PA ABIVAX SA N/A 5.34B
GLPG.AS GALAPAGOS NV N/A 1.80B

About 1VKTX.MI

Company Profile

1VKTX logo image Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 48 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Company Info

VIKING THERAPEUTICS INC

9920 Pacific Heights Blvd, Suite 350

San Diego CALIFORNIA US

Employees: 48

1VKTX Company Website

1VKTX Investor Relations

Phone: 18587044660

VIKING THERAPEUTICS INC / 1VKTX.MI FAQ

What is the stock price of VIKING THERAPEUTICS INC today?

The current stock price of 1VKTX.MI is 21.43 EUR. The price decreased by -6.99% in the last trading session.


What is the ticker symbol for VIKING THERAPEUTICS INC stock?

The exchange symbol of VIKING THERAPEUTICS INC is 1VKTX and it is listed on the Euronext Milan exchange.


On which exchange is 1VKTX.MI stock listed?

1VKTX.MI stock is listed on the Euronext Milan exchange.


What is VIKING THERAPEUTICS INC worth?

VIKING THERAPEUTICS INC (1VKTX.MI) has a market capitalization of 2.41B EUR. This makes 1VKTX.MI a Mid Cap stock.


How many employees does VIKING THERAPEUTICS INC have?

VIKING THERAPEUTICS INC (1VKTX.MI) currently has 48 employees.


What are the support and resistance levels for VIKING THERAPEUTICS INC (1VKTX.MI) stock?

VIKING THERAPEUTICS INC (1VKTX.MI) has a resistance level at 23.04. Check the full technical report for a detailed analysis of 1VKTX.MI support and resistance levels.


Should I buy VIKING THERAPEUTICS INC (1VKTX.MI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VIKING THERAPEUTICS INC (1VKTX.MI) stock pay dividends?

1VKTX.MI does not pay a dividend.


When does VIKING THERAPEUTICS INC (1VKTX.MI) report earnings?

VIKING THERAPEUTICS INC (1VKTX.MI) will report earnings on 2025-10-21, after the market close.


What is the Price/Earnings (PE) ratio of VIKING THERAPEUTICS INC (1VKTX.MI)?

VIKING THERAPEUTICS INC (1VKTX.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.31).


1VKTX.MI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to 1VKTX.MI.


Chartmill TA Rating
Chartmill Setup Rating

1VKTX.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to 1VKTX.MI. While 1VKTX.MI has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1VKTX.MI Financial Highlights

Over the last trailing twelve months 1VKTX.MI reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS decreased by -62.77% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -20.72%
ROE -21.57%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-190%
Sales Q2Q%N/A
EPS 1Y (TTM)-62.77%
Revenue 1Y (TTM)N/A

1VKTX.MI Forecast & Estimates


Analysts
Analysts85
Price TargetN/A
EPS Next Y-144.67%
Revenue Next YearN/A

1VKTX.MI Ownership

Ownership
Inst Owners69.64%
Ins Owners2.15%
Short Float %N/A
Short RatioN/A